Biomarker bioanalysis

The bioanalysis of endogenous biomarkers requires a broad range of expertise. Biomarker molecules vary extensively with respect to concentrations that need to be quantified, the biomarker class, its chemical characteristics, as well as the levels already present in the sample matrix. Another challenge could be that reference material is not available for that analyte.

In the case of biomarker analysis, the context-of-use of the analytical data is key in developing a method that is fit for the purpose.

Lablytica can analyze both large and small molecules using either enzyme-linked immunosorbent assay (ELISA), UPLC-MS/MS, or a combination of both methods (hybrid assays). We balance high throughput and high accuracy with our semi-automated processes, providing data which is both accurate and precise in a timely manner.

A few biomarkers that Lablytica has experience with are Glial fibrillary acidic protein (GFAP), S100 calcium-binding protein B (S100B), Neurofilament light protein (NFL), Prostaglandin E2 (PGE2), Urine PGs, Asymmetric dimethylarginine (ADMA), Insulin, Kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin (NGAL), rat gastrin, among others.

Lablytica supports Elypta in the development of their metabolism-based liquid biopsy platform.

For sales and project inquiries please email sales@lablytica.com

We look forward to hearing from you!